Earnings ·
Keros Therapeutics reported a net loss of $28.7 million for the quarter ended June 30, 2026, compared to a $30.7…
KROSKeros Therapeutics, Inc.
Keros Therapeutics reported a net loss of $28.7 million for the quarter ended June 30, 2026, compared to a $30.7 million loss in the prior year period. The reduction was driven by decreased research and development expenses of $21.2 million due to the transition of elritercept-related costs to Takeda and corporate restructuring, as well as lower general and administrative expenses. Cash and cash equivalents stood at $257.6 million as of June 30, 2026, with management expecting this balance to fund operations into the first half of 2028. The company also announced it has initiated a Phase 2 clinical trial for rinvatercept in patients with Duchenne muscular dystrophy (DMD). Keros Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for disorders linked to dysfunctional TGF-ß signaling.